stockportfolio.pro
Arcus Biosciences, Inc. (RCUS)
Healthcare · Biotechnology · NYSE
Arcus Biosciences, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.41M | $8.35M | $15.00M | $78.00M | $383.00M | $112.00M | $117.00M | $258.00M | $247.00M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-17.97M | $-53.08M | $-49.59M | $-84.71M | $-123.00M | $53.00M | $-267.00M | $-307.00M | $-283.00M | $-353.00M |
| Net margin | — | -3756.7% | -593.7% | -564.7% | -157.7% | 13.8% | -238.4% | -262.4% | -109.7% | -142.9% |
Source: Arcus Biosciences, Inc. SEC filings (10-K).
Explore 10 years of Arcus Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track RCUS in your portfolio →
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Arcus Biosciences, Inc. — frequently asked questions
What is Arcus Biosciences, Inc.'s revenue?
Arcus Biosciences, Inc. (RCUS) reported revenue of $247.00M for fiscal year 2025, down 4.3% from the prior year, according to its SEC filings.
Is Arcus Biosciences, Inc. profitable?
No — RCUS reported a net loss of $-353.00M in fiscal 2025.
What is RCUS's P/E ratio?
Arcus Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Arcus Biosciences, Inc. growing?
RCUS's revenue grew at roughly 25.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Arcus Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.